oa SA Pharmaceutical Journal - New drug focus



Extracted from text ... 47 SA Pharmaceutical Journal - July 2006 DRUG INFO Information supplied by Amayeza Info Services Tel : (011) 678 2332 Eplerenone (Inspra(r)) - Reduces risk of cardiovascular death after acute MI Approved indication Eplerenone is indicated to reduce the risk of cardiovascular death in stable patients with left ventricular dysfunction (ejection fraction =?40%) and clinical evidence of heart failure after acute myocardial infarction (MI). Mode of action Eplerenone is a selective aldosterone receptor antagonist. It binds to the mineralocorticoid receptor and blocks the binding of aldosterone. Eplerenone is similar in structure to spironolactone but has a lower affinity for the ..


Article metrics loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error